

# Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/NA5A73F53051EN.html>

Date: December 2019

Pages: 100

Price: US\$ 3,500.00 (Single User License)

ID: NA5A73F53051EN

## Abstracts

Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019

### SUMMARY

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019, outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an important role in inflammation. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 2, 12 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecule, respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Central Nervous System, Dermatology, Respiratory, Metabolic Disorders and Undisclosed which include indications Ulcerative Colitis, Psoriasis, Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Inflammation, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Systemic Lupus Erythematosus, T-Cell Acute Lymphocytic Leukemia (T-Cell

Acute Lymphoblastic Leukaemia), Alopecia Areata, Anaplastic Large Cell Lymphoma (ALCL), Asthma, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Hidradenitis Suppurativa, Psoriatic Arthritis, Vitiligo, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Fibrosis, Follicular Lymphoma, Hypersensitivity, Kidney Cancer (Renal Cell Cancer), Lung Transplant Rejection, Lupus Erythematosus, Lupus Nephritis, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Pancreatic Cancer, Peripheral T-Cell Lymphomas (PTCL), Skin Cancer, Unspecified and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Furthermore, this report also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their

major and minor projects

The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Overview

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics  
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics  
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies  
Involved in Therapeutics Development

AbbVie Inc

Amgen Inc

Bristol-Myers Squibb Co

Merck & Co Inc

Nimbus Therapeutics LLC

Oncostellae SL

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Sincere Pharmaceutical Group

Takeda Pharmaceutical Co Ltd

Theravance Biopharma Inc

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles  
ABBV-712 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-624 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986165 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brepocitinib tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDI-031232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDI-031301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDI-031407 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OST-122 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06826647 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-20347 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SART-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SDC-1801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SDC-1802 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAKs for Lung Transplant Rejection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TYK2 for Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TYK2 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TYK2 for Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

## R&D Progress

Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-8236 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Products

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued Products

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Dec 09, 2019: Portola Pharmaceuticals presents new interim data at the 61st ASH meeting on its oral SYK/JAK inhibitor Cerdulatinib in heavily pre-treated patients with relapsed/refractory follicular lymphoma

Dec 08, 2019: Portola Pharmaceuticals presents new interim data from ongoing phase 2a study of its oral SYK/JAK inhibitor cerdulatinib in heavily pre-treated T-Cell Malignancies

Dec 03, 2019: Theravance Biopharma announces dosing of first patient in phase 2 allergen challenge study of TD-8236, an investigational, Lung-selective, inhaled pan-janus kinase (JAK) inhibitor for inflammatory lung diseases

Dec 03, 2019: Dermavant announces first patient dosed in phase 2a clinical trial of topical dual JAK/Syk inhibitor Cerdulatinib for Vitiligo

Oct 30, 2019: Sareum presents data highlighting the anti-tumour activity of TYK2/JAK1 Inhibitor SDC-1802 in multiple cancer disease models via a novel immunotherapeutic mechanism of action

Oct 17, 2019: Sareum Holdings -Research Update -AACR-NCI-EORTC abstract

Sep 27, 2019: Sareum TYK2/JAK1 Inhibitor SDC-1802 Demonstrates Anti-tumour Activity in Multiple Cancer Disease Models

Sep 09, 2019: Theravance Biopharma reports positive results from phase 1 clinical trial of TD-8236, an investigational, lung-selective, inhaled Pan-Janus Kinase (JAK) inhibitor for inflammatory lung diseases



Jun 19, 2019: Portola presents new interim data on its oral SYK/JAK inhibitor cerdulatinib in heavily pre-treated patients with Relapsed/Refractory Follicular Lymphoma

May 21, 2019: Theravance Biopharma reports data from phase 1b study of TD-1473 in oral presentation at Digestive Disease Week (DDW) 2019

May 14, 2019: Theravance Biopharma announces data from phase 1b study of TD-1473 to be featured in oral presentation at Digestive Disease Week (DDW) 2019

Apr 23, 2019: Oncostellae expands partnering activities for OST-122 at the 2019 BIO Int'l Convention in Philadelphia

Mar 12, 2019: Theravance Biopharma announces first patient dosed in phase 2b/3 study of TD-1473 in patients with ulcerative colitis

Dec 06, 2018: Dermavant Sciences to present new data on Cerdulatinib for atopic dermatitis and vitiligo at the 3rd Annual Inflammatory Skin Disease Summit

Dec 03, 2018: Updated interim results from ongoing phase 2a study of Portola Pharmaceuticals' oral Syk/JAK inhibitor Cerdulatinib continues to demonstrate clinical responses in heavily pre-treated T-Cell Malignancies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indications, H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Products under Development by Companies, H2 2019 (Contd..2), H2 2019  
Products under Development by Companies, H2 2019 (Contd..3), H2 2019  
Products under Development by Companies, H2 2019 (Contd..4), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by AbbVie Inc, H2 2019  
Pipeline by Amgen Inc, H2 2019  
Pipeline by Bristol-Myers Squibb Co, H2 2019  
Pipeline by Merck & Co Inc, H2 2019  
Pipeline by Nimbus Therapeutics LLC, H2 2019  
Pipeline by Oncostellae SL, H2 2019  
Pipeline by Pfizer Inc, H2 2019  
Pipeline by Portola Pharmaceuticals Inc, H2 2019  
Pipeline by Sareum Holdings Plc, H2 2019  
Pipeline by Simcere Pharmaceutical Group, H2 2019  
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019  
Pipeline by Theravance Biopharma Inc, H2 2019  
Dormant Projects, H2 2019  
Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

AbbVie Inc

Amgen Inc

Bristol-Myers Squibb Co

Merck & Co Inc

Nimbus Therapeutics LLC

Oncostellae SL

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Simcere Pharmaceutical Group

Takeda Pharmaceutical Co Ltd

Theravance Biopharma Inc

## I would like to order

Product name: Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/NA5A73F53051EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NA5A73F53051EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970